Medical Research Commercialisation Fund

The Medical Research Commercialisation Fund, now known as Brandon BioCatalyst, operates as an investment collaboration dedicated to advancing early-stage biomedical discoveries. It unites over 50 leading medical research institutes and hospitals across Australia and New Zealand with significant investment from superannuation funds and governments. This unique structure provides both the essential capital and specialized expertise required to guide the translation and commercialisation of nascent health technologies, fostering the creation of new biotech companies.

The collaboration was founded in 2007 by Chris Nave, Stephen Thompson, and David Fisher. Their foundational insight stemmed from a recognition of the untapped potential within Australia's world-class life science research, coupled with a critical need for dedicated funding and commercialisation support to bring these discoveries to fruition. The initial Medical Research Commercialisation Fund served as a working title for this pioneering initiative, growing significantly since its inception.

Brandon BioCatalyst serves its member research organizations by providing a pathway for their emerging medical discoveries to become commercially viable therapies. The long-term vision is to improve patient outcomes through new treatments, stimulate economic growth by creating jobs, and cultivate a robust, self-sustaining biotech sector in Australia and New Zealand. Ultimately, the aim is to foster the emergence of significant, homegrown biotech success stories.